Schrodinger (NASDAQ:SDGR – Get Free Report) and Movano (NASDAQ:MOVE – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, valuation, dividends, profitability, risk and analyst recommendations.
Volatility and Risk
Schrodinger has a beta of 1.57, indicating that its share price is 57% more volatile than the S&P 500. Comparatively, Movano has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500.
Institutional & Insider Ownership
79.1% of Schrodinger shares are owned by institutional investors. Comparatively, 16.6% of Movano shares are owned by institutional investors. 10.1% of Schrodinger shares are owned by company insiders. Comparatively, 10.4% of Movano shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Schrodinger | $255.87 million | 3.45 | -$103.26 million | ($1.41) | -8.48 |
| Movano | $430,000.00 | 52.30 | -$18.28 million | ($10.61) | -1.88 |
Movano has lower revenue, but higher earnings than Schrodinger. Schrodinger is trading at a lower price-to-earnings ratio than Movano, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Schrodinger and Movano’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Schrodinger | -40.61% | -30.85% | -15.32% |
| Movano | -4,231.41% | -647.91% | -298.12% |
Analyst Ratings
This is a breakdown of current ratings and price targets for Schrodinger and Movano, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Schrodinger | 1 | 4 | 4 | 0 | 2.33 |
| Movano | 1 | 0 | 0 | 0 | 1.00 |
Schrodinger currently has a consensus target price of $20.25, suggesting a potential upside of 69.46%. Given Schrodinger’s stronger consensus rating and higher possible upside, equities analysts clearly believe Schrodinger is more favorable than Movano.
Summary
Schrodinger beats Movano on 10 of the 14 factors compared between the two stocks.
About Schrodinger
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
About Movano
Movano Inc. engages in developing a platform to deliver healthcare solutions at the intersection of medical and consumer devices. The company is involved in the development of Evie Ring, which is a wearable designed specifically for women that combines health and wellness metrics comprises resting heart rate, heart rate variability (HRV), blood oxygen saturation (SpO2), respiration rate, skin temperature variability, period and ovulation tracking, and menstrual symptom tracking, as well as activity profile, including steps, active minutes and calories burned, sleep stages and duration, and mood tracking. It develops System-on-a-Chip (SoC) for blood pressure or continuous glucose monitoring (CGM) systems. The company was formerly known as Maestro Sensors Inc. and changed its name to Movano Inc. in August 2018. Movano Inc. was incorporated in 2018 and is based in Pleasanton, California.
Receive News & Ratings for Schrodinger Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Schrodinger and related companies with MarketBeat.com's FREE daily email newsletter.
